East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Memantine Hydrochloride Extended-Release Capsules, 7mg, 14mg, 21mg, and 28mg. Aurobindo Pharma’s Memantine Hydrochloride Extended-Release Capsules, 7mg, 14mg, 21mg, and 28mg are an AB-rated generic equivalent to the reference listed drug (RLD), Namenda XR of Forest Laboratories LLC.

Memantine Hydrochloride Extended-Release Capsules are indicated for:

• The treatment of moderate to severe dementia of the Alzheimer’s type.